Genomic Testing in Brazil: Navigating Challenges and Harnessing Opportunities for Global Health Impact 2. Trial visits are kept to a minimum with potential utilization of telemedicine or stipends ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial Colorectal cancer (CRC) remains a major global ...

Reply to: Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm–Derived Pancreatic Cancer: Addressing Statistical and Methodological Concerns in Survival Analysis ASCO Guidelines ...

Cancer treatment often involves significant toxicity and interruptions to daily life. As a result, patient-reported outcomes (PROs) such as health-related quality of life (HRQoL) are an essential ...

Fig 1. Minimum-maximum symptom prevalence (%) for patients with cancer (n = total number of patients involved in the studies for each symptom). Adapted from systematic review findings of Solano et al.

Extension for Community Healthcare Outcomes-Palliative Care in Africa and Quality of Life, Symptoms, Patient Experience, and Caregiver Distress Among Patients With Cancer The findings emphasize the ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...